Neue Pharmaka zur Behandlung der chronisch-obstruktiven Lungenerkrankung (COPD)

Zusammenfassung

Aktuell werden viele neue langwirksame Bronchodilatatoren einzeln, als Fix-Kombinationspräparate oder in Kombination mit einem inhalativen Kortikosteroid zur COPD-Behandlung in den Markt eingeführt. Die meisten Neuzulassungen sind zudem mit der Neueinführung von neuen Inhalationssystemen verbunden. Es sind auch Trippel-Fix-Kombinationen in der Entwicklung, die alle drei Wirkprinzipien, d. h. drei Substanzen, beinhalten. Die COPD-Therapie wird dadurch differenzierter und auch komplizierter. Diese Übersicht gibt einen aktuellen Einblick in den aktuellen Entwicklungsstand und wagt einen Blick in die mittelbare Zukunft.

Abstract

Currently, numerous new compounds and inhaler types are reaching the market for the treatment of chronic obstructive pulmonary disease (COPD). They comprise new long-acting beta-2 agonists, muscarinic antagonists and inhaled corticosteroids. Most of them are for combination treatment in new fixed-dose inhalers. Even the combination of three components in one inhaler is under development. Thus, management of COPD are getting more differentiated but also much more complex. This review gives an overview of the state of art of pharmaceutical research in this area and offers a glimpse into the proximate future.

• Literatur

• 1 Lopez AD, Murray CC. The global burden of diseases. Natur Med 1998; 4 1241-1243
• 2 Murray CJ L, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349 1269-1276
• 3 Geldmacher H, Biller H, Herbst A et al. Die Prävalenz der chronisch-obstruktiven Lungenerkrankung (COPD) in Deutschland. Dtsch Med Wschr 2008; 133: 2609-2614
• 4 Gillissen A, Lommatzsch M, Prenzler A, Schulenburg Graf v. d. J-M. Chronisch obstruktive Lungenerkrankung (COPD). In: Gillissen A, Welte T, (Hrsg). Weißbuch Lunge 2014. Die Lunge und ihre Erkrankungen: Zur lage und Zukunft der Pneumologie ind Deutschland. Herne: Frischtexte Verlag; 2014: 47-57
• 5 GOLD Executive Committee. Global initiative for chronic obstructive lung disease. www.goldcopd.com 2014
• 6 Fabbri LM, Calverley PM A, Izquierdo-Alonso JL et al. Roflumilast in moderate to severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised trials. Lancet 2009; 374: 695-703
• 7 Calverley PM A, Rabe KF, Goehring U-M et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694
• 8 De Savi C, Cox RJ, Warner DJ et al. Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD. J Med Chem 2014; [im Druck]
• 9 Hamblin JN, Angell TD, Ballantine SP et al. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg Med Chem Lett 2008; 18: 4237-4241
• 10 Tannheimer SL, Sorensen EA, Cui ZH et al. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting beta2-adrenoceptor agonist. J Pharmacol Exp Ther 2014; 349: 85-93
• 11 Donohue JF, Fogarty C, Lötvall J et al. Once daily bronchodilators of chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2011; 182: 155-162
• 12 Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways disease. Adv.Ther 2009; 26 : 691-699
• 13 Gibb A, Yang LP. Olodaterol: first global approval. Drugs 2013; 73: 1841-1846
• 14 Ulrik CS. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. Int J Chron Obstruct Pulmon Dis 2014; 9: 331-338
• 15 D'Urzo A. Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD. Ther.Clin.Risk Manag 2013; 9 : 341-353
• 16 Molimard M, D'Andrea P. Once-daily glycopyrronium via the Breezhaler(R) device for the treatment of COPD: pharmacological and clinical profile. Expert Rev Clin Pharmacol 2013; 6: 503-517
• 17 Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis 2012; 7: 673-678
• 18 Chanez P, Burge PS, Dahl R et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Therapeutics 2010; 23: 15-21
• 19 Joos GF, Schelfhout VJ, Pauwels RA et al. Bronchodilatory effects of aclidinium bromide, along-acting muscarinic antagonist in COPD patients. Respir Med 2010; 104: 865-872
• 20 Chanez P, Burge S, Dahl J et al. Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a phase II, dose-finding study. Am J Respir Crit Care Med 2008; 177: A349
• 21 Ärztliches Zentrum für Qualität in der Medizin (ÄZQ). Nationale Versorgungsleitlinie COPD. Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften AWMF and Bundesä. (1.8), 2011 (GENERIC) Ref Type: Online Source 1-99 www.versorgungsleitlinien.de
• 22 Noord van J A, Aumann J, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 124: 1743-1748
• 23 Noord van J A, Aumann J, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and combinded once daily in patients with COPD. Eur Respir J 2005; 26: 214-222
• 24 Bateman ED, Mahler DA, Vogelmeier CF et al. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med 2014; 8: 357-379
• 25 Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209
• 26 Frampton JE. QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease. Drugs 2014; 74: 465-488
• 27 Svedsater H, Dale P, Garrill K et al. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013; 13-72
• 28 Caramori G, Chung KF, Adcock IM. Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 249-256
• 29 Agusti A, de T L, De B W et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014; 43: 763-772
• 30 Dransfield MT, Bourbeau J, Jones PW et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210-223
• 31 Kerwin EM, Scott-Wilson C, Sanford L et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respir Med 2013; 107: 560-569
• 32 Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. Eur Respir J 2014; [im Druck]
• 33 Scott LJ, Hair P. Umeclidinium/Vilanterol: first global approval. Drugs 2014; 74: 389-395
• 34 Traynor K. Umeclidinium-vilanterol inhaler approved for COPD. Am J Health Syst Pharm 2014; 71: 174
• 35 Church A, Beerahee M, Brooks J et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulm Med 2014; 14: 2
• 36 Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis 2013; 7: 311-319